Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 2Phase 2/3 2Phase 4 1Phase 1/2 1Phase 1 1

Status

Completed 16Recruiting 5Terminated 3Withdrawn 2Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

pembrolizumab 85Cyclophosphamide 74Nivolumab 58fludarabine 49Specimen Handling 49Magnetic Resonance Spectroscopy 43Carboplatin 41Biopsy 39Radiotherapy 32fludarabine phosphate 30atezolizumab 27Gemcitabine 27Paclitaxel 26Ipilimumab 26Cisplatin 24venetoclax 23Radiation 23Dexamethasone 22Radiosurgery 21durvalumab 20Rituximab 20Temozolomide 18Lenalidomide 18Bevacizumab 17palbociclib 15Pemetrexed 15Decitabine 15Cytarabine 15130-nm albumin-bound paclitaxel 15Oxaliplatin 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × Thiotepa × Clear all
NCT05088356 2026-05-12

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Stanford University

Phase 1 Active not recruiting
66 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡